US Bancorp DE Sells 404 Shares of U.S. Physical Therapy, Inc. (NYSE:USPH)

US Bancorp DE lessened its holdings in U.S. Physical Therapy, Inc. (NYSE:USPHFree Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,439 shares of the company’s stock after selling 404 shares during the period. US Bancorp DE owned 0.08% of U.S. Physical Therapy worth $1,065,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in USPH. SRS Capital Advisors Inc. raised its stake in U.S. Physical Therapy by 308.0% in the 4th quarter. SRS Capital Advisors Inc. now owns 408 shares of the company’s stock valued at $38,000 after acquiring an additional 308 shares during the period. Quantbot Technologies LP bought a new position in U.S. Physical Therapy during the 3rd quarter worth $82,000. Principal Securities Inc. bought a new position in U.S. Physical Therapy during the 4th quarter worth $100,000. Benjamin Edwards Inc. increased its position in U.S. Physical Therapy by 17.4% during the 4th quarter. Benjamin Edwards Inc. now owns 1,692 shares of the company’s stock worth $158,000 after buying an additional 251 shares during the period. Finally, Thoroughbred Financial Services LLC bought a new position in U.S. Physical Therapy during the 4th quarter worth $223,000.

U.S. Physical Therapy Stock Performance

USPH opened at $98.27 on Tuesday. The firm has a market cap of $1.48 billion, a P/E ratio of 79.89, a price-to-earnings-growth ratio of 3.91 and a beta of 1.41. U.S. Physical Therapy, Inc. has a 52-week low of $78.08 and a 52-week high of $124.11. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.16 and a current ratio of 2.16. The business’s fifty day moving average is $104.12 and its 200-day moving average is $98.87.

U.S. Physical Therapy (NYSE:USPHGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.07). The business had revenue of $155.70 million during the quarter, compared to analyst estimates of $153.30 million. U.S. Physical Therapy had a net margin of 4.72% and a return on equity of 8.03%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business earned $0.59 earnings per share. Sell-side analysts expect that U.S. Physical Therapy, Inc. will post 2.9 EPS for the current fiscal year.

U.S. Physical Therapy Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Thursday, May 23rd will be paid a $0.44 dividend. This represents a $1.76 annualized dividend and a yield of 1.79%. The ex-dividend date is Wednesday, May 22nd. U.S. Physical Therapy’s dividend payout ratio (DPR) is presently 143.09%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. JPMorgan Chase & Co. increased their price objective on U.S. Physical Therapy from $99.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Barrington Research reiterated an “outperform” rating and set a $122.00 price objective on shares of U.S. Physical Therapy in a research report on Thursday, May 9th. Finally, StockNews.com raised U.S. Physical Therapy from a “sell” rating to a “hold” rating in a report on Monday, March 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, U.S. Physical Therapy has an average rating of “Moderate Buy” and a consensus price target of $125.67.

Read Our Latest Analysis on USPH

Insider Activity at U.S. Physical Therapy

In related news, CEO Christopher J. Reading sold 2,900 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $100.26, for a total value of $290,754.00. Following the sale, the chief executive officer now directly owns 95,838 shares of the company’s stock, valued at $9,608,717.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other U.S. Physical Therapy news, CEO Christopher J. Reading sold 1,100 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $102.13, for a total value of $112,343.00. Following the completion of the transaction, the chief executive officer now directly owns 99,738 shares in the company, valued at $10,186,241.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher J. Reading sold 2,900 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $100.26, for a total value of $290,754.00. Following the completion of the transaction, the chief executive officer now owns 95,838 shares of the company’s stock, valued at $9,608,717.88. The disclosure for this sale can be found here. Insiders have sold 14,924 shares of company stock valued at $1,563,389 over the last ninety days. 1.70% of the stock is owned by corporate insiders.

U.S. Physical Therapy Profile

(Free Report)

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

See Also

Institutional Ownership by Quarter for U.S. Physical Therapy (NYSE:USPH)

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.